STOK — Stoke Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $761.81m
- $479.83m
- $8.78m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 222 | 287 | 220 | 230 | 201 |
Net Total Receivables | 0.281 | 0.006 | 0.132 | 0.588 | 0.064 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 226 | 294 | 229 | 244 | 215 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.51 | 3.79 | 9.08 | 11.4 | 12.4 |
Other Long Term Assets | |||||
Total Assets | 229 | 298 | 239 | 256 | 228 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.1 | 11.4 | 17.1 | 31.4 | 30.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.32 | 11.8 | 21.1 | 71.2 | 68.8 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 224 | 286 | 218 | 185 | 160 |
Total Liabilities & Shareholders' Equity | 229 | 298 | 239 | 256 | 228 |
Total Common Shares Outstanding |